1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [edd0365d-037c-4a51-85f9-fc17b5481bb7] => Array
        (
            [runtime-id] => edd0365d-037c-4a51-85f9-fc17b5481bb7
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [e6458754-de08-4f3a-b608-67419b83cac7] => Array
                        (
                            [runtime-id] => e6458754-de08-4f3a-b608-67419b83cac7
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;9e7e2fe00bf7a419c7770511fd165793b673c536
                )

        )

)
1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [c77e44f2-3cce-4440-88be-da05868fcc67] => Array
        (
            [runtime-id] => c77e44f2-3cce-4440-88be-da05868fcc67
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [007a4221-e3e5-4f6b-910f-5dca7032cb62] => Array
                        (
                            [runtime-id] => 007a4221-e3e5-4f6b-910f-5dca7032cb62
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;9e7e2fe00bf7a419c7770511fd165793b673c536
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Xiang, Y.
AU  - Zhao, H.
AU  - Ding, C.
AU  - Chen, H.
AU  - Wang, D.
AU  - Liu, A.
TI  - The Prophylactic Use of Tirofiban versus Oral Antiplatelet Medications in Stent-Assisted Coiling of Intracranial Aneurysms: A Meta-analysis
AID  - 10.3174/ajnr.A6996
DP  - 2021 Apr 01
TA  - American Journal of Neuroradiology
PG  - 713--719
VI  - 42
IP  - 4
4099  - http://www.ajnr.org/content/42/4/713.short
4100  - http://www.ajnr.org/content/42/4/713.full
SO  - Am. J. Neuroradiol.2021 Apr 01; 42
AB  - BACKGROUND: The protocol for optimal antiplatelet therapy to prevent thromboembolic and hemorrhagic complications in patients with cerebral aneurysms using an endovascular approach is not clear.PURPOSE: Our study analyzed the safety and efficacy of prophylactic tirofiban administration compared with oral antiplatelet drug therapy.DATA SOURCES: We used the PubMed, EMBASE, MEDLINE, and Cochrane library data bases.STUDY SELECTION: Our study consisted of all case series with &amp;gt;5 patients that reported treatment-related outcomes of patients undergoing endovascular procedures pretreated with tirofiban or oral antiplatelet drug therapy.DATA ANALYSIS: Random effects or fixed effects meta-analysis was used to pool the cumulative rate of complications, perioperative mortality, and good clinical outcomes.DATA SYNTHESIS: Fifteen studies with 1981 patients were registered. Thromboembolic complications were significantly lower in the tirofiban group (3.6%; 95% CI, 1.9%–5.8%) compared with the dual-antiplatelet therapy group (8.5%, 95% CI, 4.5%–13%; P = .04). Pretreatment with tirofiban did not remarkably increase the rate of hemorrhagic complications (3.5%; 95% CI, 1.8%–5.6%) compared with dual-antiplatelet therapy (5.1%; 95% CI, 2.6%–8.5%; P = .371). There was a trend toward lower perioperative mortality with tirofiban (0.8%; 95% CI, 0.2%–1.6%) compared with dual-antiplatelet therapy (1.2%; 95% CI, 0.7%–2.0%; P = .412). There was no significant difference in the safety and efficacy between the tirofiban bolus plus drip and drip alone.LIMITATIONS: The limitations are selection and publication biases.CONCLUSIONS: Prophylactic therapy with tirofiban resulted in significantly lower rates of thromboembolic complications with no increase in hemorrhagic events or mortality than the prophylactic use of dual-antiplatelet therapy.ASAacetylsalicylic acidDAPTdual-antiplatelet therapyGP IIb/IIIaglycoprotein IIb/IIIaMINORSmethodological index for nonrandomized studiesPRISMAPreferred Reporting Items for Systematic Review and Meta-Analysis